Methods and compositions for treating melanoma and non-melanoma skin cancers

1. A method for the treatment of non-melanoma and/or melanoma skin cancers said method comprising administering, topically, orally, intravenously, intraperitoneally and/or subcutaneously, a therapeutically effective amount of (a) a composition comprising at least one compound according to Structure 1

wherein R 1 , R 2 , R 3 , R 4 and R 5 , which may be the same or different, are each independently H, OH, alkyl or alkoxy, provided that at least one of R 1 , R 2 , R 3 , R 4 and R 5 is not H, and wherein the alkyl or alkoxy groups, if present, are linear or branched and have, from 1 to 8 carbon atoms, alone or in combination with (b) at least one anti-cancer therapeutic active agent.

2. The method of claim 1 wherein R 1 and R 2 are H and R 3 , R 4 and R 5 , which may be the same or different, are each independently H, OH, or C 1 to C 4 alkoxy, provided that at least one of R 3 , R 4 and R 5 is not H.

3. The method of claim 1 wherein R 1 and R 2 are H and R 3 , R 4 and R 5 , which may be the same or different, are each independently H, OH, or OCH 3 ; provided at least one or two of R 3 , R 4 and R 5 is OH or OCH 3 or one of R 3 , R 4 and R 5 is OH and at least one of the remaining moieties is OH or OCH 3 .

4. The method of claim 1 wherein the at least one compounds according to Structure 1 is selected from the group consisting of:

Compound 1: R 1 ═R 2 ═R 5 ═H; R 3 ═OH; and R 4 ═OCH 3 ;

Compound 2: R 1 ═R 2 ═R 4 ═R 5 ═H; and R 3 ═OCH 3 ;

Compound 3: R 1 ═R 2 ═R 4 ═R 5 ═H; and R 3 ═OH;

Compound 4: R 1 ═R 2 ═R 3 ═R 5 ═H; and R 4 ═OH;

Compound 5: R 1 ═R 2 ═R 3 ═R 5 ═H; and R 4 ═OCH 3 ;

Compound 6: R 1 ═R 2 ═R 3 ═R 4 ═H; and R 5═0 H;

Compound 7: R 1 ═R 2 ═R 3 ═R 4 ═H; and R 5 ═OCH 3 ; and

Compound 8: R 1 ═R 3 ═R 5 ═H; and R 2 ═R 4 ═OH.

5. The method of claim 1 wherein the at least one anti-cancer therapeutic active agent is also administered and is a compound or composition know or believed to be effective in treating melanoma and/or non-melanoma skin cancer.

6. The method of claim 5 wherein the at least one anti-cancer therapeutic active agent is selected from the group consisting of dacarbazine, an AMPK activator; an immune checkpoint inhibitor (ICI); a BRAF and/or MEK inhibitors, dabrafenib (Tafinlar), trametinib (Mekinist), vemurafenib (Zelboraf), cobimetinib (Cotellic), encorafenib (Braftovi), binimetinib (Mektovi), a PD-1 inhibitor, pembrolizumab (Keytruda), nivolumab (Opdivo), a CTLA-4 inhibitor, ipilimumab (Yervoy), and combinations of any two or more of the foregoing.

7. The method of claim 1 wherein the composition(s) further comprises a pharmaceutically acceptable carrier for the given mode of administration.

8. The method of claim 5 wherein the at least one compound according to Structure 1 and the at least one anti-cancer therapeutic active agent are administered at the same time, either as a single administration or in separate but concurrent administrations.

9. The method of claim 5 wherein the at least one compound according to Structure 1 and the at least one anti-cancer therapeutic active agent are administered separately at different times.

10. The method of claim 9 wherein the at least one compound according to Structure 1 and the at least one anti-cancer therapeutic active agent are administered separately at different times in a staggered or alternating regimen.

11. The method of claim 1 wherein the compound(s) according to Structure 1 is(are) present in an amount of from 0.05 to 25 percent by weight based on the total weight of the composition administered and containing the same.

12. The method of claim 1 wherein the compound(s) according to Structure 1 is(are) present in an amount of from 0.1 to 20 percent by weight based on the total weight of the composition administered and containing the same.

13. The method of claim 1 wherein the compound(s) according to Structure 1 is(are) present in an amount of from 0.5 to 15 percent by weight based on the total weight of the composition administered and containing the same.

14. The method of claim 1 wherein the other anti-cancer (agents) is present in its(their) conventional therapeutically effective amount(s).

15. The method of claim 11 wherein the other anti-cancer agent(s) is present in its(their) conventional therapeutically effective amount(s).

16. The method of claim 12 wherein the other anti-cancer agent(s) is present in its(their) conventional therapeutically effective amount(s).

17. The method of claim 13 wherein the other anti-cancer agent(s) is present in its(their) conventional therapeutically effective amount(s).

18. The method of claim 6 wherein the other anti-cancer therapeutic active agent is selected from the group consisting of dabrafenib (Tafinlar), trametinib (Mekinist), vemurafenib (Zelboraf), cobimetinib (Cotellic), encorafenib (Braftovi), binimetinib (Mektovi), pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy).

19. The method of claim 6 wherein the other anti-cancer therapeutic active agent is trametinib (Mekinist).

20. The method of claim 6 wherein the other anti-cancer therapeutic active agent is pembrolizumab (Keytruda).

21. The method of claim ( 6 ) wherein the other anti-cancer therapeutic active agent is selected from a combination of nivolumab (Opdivo) and ipilimumab (Yervoy), a combination of dabrafenib (Tafinlar) and trametinib (Mekinist), a combination of vemurafenib (Zelboraf) and cobimetinib (Cotellic), and a combination of encorafenib (Braftovi) and binimetinib (Mektovi).